Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H U Group HoldingsMRCHF 65 Debt-to-EBITDA is 2.87 as of Mar. 2026, which is 20% above its 10-year median of 2.39. GuruFocus rates MRCHF with a GF Score™ of 65/100 and a GF Value™ of $18.85 (Fairly Valued). The stock has 6 warning signs investors should review. Among 113 Medical Diagnostics & Research companies, H U Group Holdings ranks worse than 53.1% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for H U Group Holdings's Debt-to-EBITDA or its related term are showing as below:
MRCHF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.57 Med: 2.39 Max: 6
Current: 2.4
During the past 13 years, the highest Debt-to-EBITDA Ratio of H U Group Holdings was 6.00. The lowest was 0.57. And the median was 2.39.
MRCHF's Debt-to-EBITDA is ranked worse than 53.1% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs MRCHF: 2.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
H U Group Holdings Debt-to-EBITDA Related Terms
H U Group Holdings Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for H U Group Holdings's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRCHF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, H U Group Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H U Group Holdings Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, H U Group Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where H U Group Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
H U Group Holdings (MRCHF) has a Debt-to-EBITDA of 2.87 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on H U Group Holdings. This is 20% above median its historical median of 2.39. Over the past decade, H U Group Holdings' Debt-to-EBITDA has ranged from 0.57 to 6.00. According to the industry distribution chart, H U Group Holdings ranks #60 out of 113 companies in the Medical Diagnostics & Research industry, placing it in the top 53.1%.
Is H U Group Holdings' Debt-to-EBITDA too high?
H U Group Holdings' current Debt-to-EBITDA of 2.87 is 20% above median its 10-year median of 2.39. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 6.00. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.32. H U Group Holdings' value of 2.87 is 23.7% above this industry median. Based on the distribution chart, H U Group Holdings ranks #60 out of 113 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, H U Group Holdings has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H U Group Holdings' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, H U Group Holdings ranks #60 out of 113 companies for Debt-to-EBITDA. This places H U Group Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 2.32. H U Group Holdings' value of 2.87 is 23.7% above this benchmark. Historically, H U Group Holdings' own Debt-to-EBITDA has ranged from 0.57 to 6.00 over the past decade. While the company's 10-year median is 2.39 vs. the industry median of 2.32, H U Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H U Group Holdings's current Debt-to-EBITDA of 2.87 is 23.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on H U Group Holdings. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H U Group Holdings's current Debt-to-EBITDA is 2.87, which is 20% above median its own 10-year median of 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H U Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, H U Group Holdings (MRCHF) is currently considered Fairly Valued. The stock's GF Value™ is $18.85, compared to a current price of $20.38 — trading 8.1% above its estimated fair value. The current Debt-to-EBITDA is 2.87, which is 20% above median its 10-year median of 2.39 and 23.7% above the Medical Diagnostics & Research industry median of 2.32. H U Group Holdings' overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For H U Group Holdings (MRCHF), the current Debt-to-EBITDA is 2.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H U Group Holdings (MRCHF) Overvalued in 2026?
Based on GuruFocus' analysis, H U Group Holdings stock appears to be overvalued.
The current stock price of $20.38 is trading 8.1% above its estimated GF Value™ of $18.85.
GuruFocus considers H U Group Holdings to be Fairly Valued.
Key valuation signals for MRCHF:
Debt-to-EBITDA: 2.87 (20% above median its 10-year median of 2.39)
GF Value™: $18.85 vs. price of $20.38 (8.1% above fair value)
Industry Position: 23.7% above the Medical Diagnostics & Research median (#60 of 113)
No single metric tells the full story. See the MRCHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
H U Group Holdings Inc operates in the healthcare field, focusing on clinical laboratory testing and reagents. The company is engaged in four main businesses. The Clinical Laboratory Testing Business receives samples taken from patients at medical institutions to test for the disease and confirm the condition of the patient's health; In Vitro Diagnostics develops, manufactures, and sells testing reagents and equipment inside and outside Japan; Sterilization & Related Services Business provides a range of medical-related services including sterilization; and Emerging New Business & Others is a new business for future growth.
65GF Score
Get the complete analysis for MRCHF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRCHF has been successfully added to your 
